ArticleBrain and behavior2026
Dexmedetomidine Inhibition of GABA Neurons in the Ventral Tegmental Area Attenuates the Depth of Sedation in Mice.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionDexmedetomidine is a sedative anesthetic with a unique ability to produce an arousable state of sedation. However, the neural mechanisms underlying this arousable sedation remain incompletely understood. Previous studies have implicated dopaminergic neurons in the ventral tegmental area (VTA) in mediating this effect, but the upstream neural circuit mechanisms remain unclear. Furthermore, although VTA GABAergic neurons exert robust inhibitory effects on dopaminergic neurons, their specific role in dexmedetomidine-induced arousable sedation remains unclear.
methodsVgat-Cre transgenic mice were used to investigate the role of VTA GABAergic neurons in dexmedetomidine-induced arousable sedation. Electroencephalography (EEG), fiber photometry, calcium imaging, GABA neurotransmitter sensing, chemogenetic manipulation, and immunohistochemistry were used to assess neuronal activity, GABAergic signaling, and behavioral responses to dexmedetomidine.
resultsFiber photometry using the calcium indicator GCaMP6m revealed that dexmedetomidine inhibited VTA GABAergic neurons. Fiber photometry with the GABA neurotransmitter sensor iGABASnFR demonstrated that dexmedetomidine increased GABAergic input to VTA GABAergic neurons. Chemogenetic manipulation combined with EEG demonstrated that activating VTA GABAergic neurons deepened dexmedetomidine-induced sedation, whereas inhibiting these neurons attenuated sedation.
conclusionThese findings suggest that dexmedetomidine increases GABAergic input to VTA GABAergic neurons and suppresses their activity, potentially contributing to its arousable sedative effects. Further studies are needed to establish the causal role of this neural circuit mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.